China approves Y-mabs drug
Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.
by albert rønning-andersson, translated by catherine brett
A new phase of the collaboration between Danish-American firm Y-mabs and Chinese company Sciclones is starting.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA confirms rejection of Y-mabs cancer drug
For subscribers
Y-mabs suffers 16-0 defeat at FDA vote
For subscribers
